Skin α-synuclein aggregation in Parkinson’s disease


  • Skin pathological α-synuclein (αSynP) seeding activity may serve as a novel biomarker for antemortem diagnosis of Parkinson’s disease (PD) and other synucleinopathies.

Why this matters

  • Brain deposition of (αSynP) is a hallmark feature of synucleinopathies including PD, Lewy body dementia (LBD) and multiple system atrophy (MSA), but whether skin-based αSynP aggregation is detectable in these disorders is unknown.

  • Identification of an early, less invasive and more cost-effective biomarker test for people at high risk of developing synucleinopathies may have implications for early initiation of treatment, thus improving patient longevity and quality of life.